Anxious and Depressive Symptoms in Parkinson's Disease: The French Cross-Sectionnal DoPAMiP Study
Identifieur interne : 001F70 ( Main/Exploration ); précédent : 001F69; suivant : 001F71Anxious and Depressive Symptoms in Parkinson's Disease: The French Cross-Sectionnal DoPAMiP Study
Auteurs : Laurence Negre-Pages [France] ; Hélène Grandjean [France] ; Maryse Lapeyre-Mestre [France] ; Jean Louis Montastruc [France] ; Annie Fourrier [France] ; Jean Pierre Lepine [France] ; Olivier Rascol [France]Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Anxiety has been less extensively studied than depression in Parkinson's disease (PD). The DoPaMiP survey allowed assessing simultaneously anxiety and depressive symptoms in PD and comparing correlations of both symptoms with clinical and therapeutic features of the disease. Cross sectional survey conducted prospectively in 450 ambulatory nondemented PD patients and 98 patients with other disorders than PD. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), parkinsonism using the Unified Parkinson's Disease Rating Scale (UPDRS). Other clinical factors were measured using a structured standardized examination/questionnaire. The mean HADS-A (anxiety) subscore was higher in PD patients than in the others (8.2 ± 3.9 vs. 6.5 ± 3.2, P < 10-4) as was the HADS-D (depressive) subscore (6.6 ± 3.8 vs. 3.9 ± 3.2, P < 10-4). Patients with possible/probable anxious signs (HADS-A ≥ 8) were more prevalent in PD (51% vs. 29%, P < 10-4) as were those with depressive symptoms (40% vs. 10%, P < 10-4). Conversely, anxiolytic and antidepressant medications consumption was not different between the 2 groups. Patients with anxious symptoms were more frequently female and younger than those without such symptoms, while those with depressive symptoms had more severe indices of parkinsonism, more comorbidities and lower cognitive function (Mini Mental State Exam). The logistic regression model revealed that patients with depressive symptoms received more frequently levodopa and less frequently a dopamine agonist. Anxiety and depressive symptoms were more frequent in PD patients than in medical control group. Both symptoms were commonly associated in the same PD patients, but were correlated with different clinical/therapeutic features, suggesting different underlying pathophysiological mechanisms.
Affiliations:
- France
- Midi-Pyrénées
- Bordeaux, Paris, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000A84
- to stream PascalFrancis, to step Curation: 002235
- to stream PascalFrancis, to step Checkpoint: 000B98
- to stream Main, to step Merge: 002785
- to stream Main, to step Curation: 001F70
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Anxious and Depressive Symptoms in Parkinson's Disease: The French Cross-Sectionnal DoPAMiP Study</title><author><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>LN-Pharma</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Grandjean, Helene" sort="Grandjean, Helene" uniqKey="Grandjean H" first="Hélène" last="Grandjean">Hélène Grandjean</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>INSERM U-558, "Epidemiology and Public Health Analyses", Faculty of Medicine</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fourrier, Annie" sort="Fourrier, Annie" uniqKey="Fourrier A" first="Annie" last="Fourrier">Annie Fourrier</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Inserm U-657 "Pharmaco-Épidémiology and Impact of Medicinal Product on Population" and Victor Segalen Bordeaux2, Pellegrin University, Bordeaux University Hospital</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Lepine, Jean Pierre" sort="Lepine, Jean Pierre" uniqKey="Lepine J" first="Jean Pierre" last="Lepine">Jean Pierre Lepine</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Fernand Widal Hospital, APHP, INSERM U 705 CNRS UMR 7157</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>INSERM U-825/CIC, Höpital Purpan</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0303302</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0303302 INIST</idno><idno type="RBID">Pascal:10-0303302</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A84</idno><idno type="wicri:Area/PascalFrancis/Curation">002235</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000B98</idno><idno type="wicri:doubleKey">0885-3185:2010:Negre Pages L:anxious:and:depressive</idno><idno type="wicri:Area/Main/Merge">002785</idno><idno type="wicri:Area/Main/Curation">001F70</idno><idno type="wicri:Area/Main/Exploration">001F70</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Anxious and Depressive Symptoms in Parkinson's Disease: The French Cross-Sectionnal DoPAMiP Study</title><author><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>LN-Pharma</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Grandjean, Helene" sort="Grandjean, Helene" uniqKey="Grandjean H" first="Hélène" last="Grandjean">Hélène Grandjean</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>INSERM U-558, "Epidemiology and Public Health Analyses", Faculty of Medicine</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fourrier, Annie" sort="Fourrier, Annie" uniqKey="Fourrier A" first="Annie" last="Fourrier">Annie Fourrier</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Inserm U-657 "Pharmaco-Épidémiology and Impact of Medicinal Product on Population" and Victor Segalen Bordeaux2, Pellegrin University, Bordeaux University Hospital</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Lepine, Jean Pierre" sort="Lepine, Jean Pierre" uniqKey="Lepine J" first="Jean Pierre" last="Lepine">Jean Pierre Lepine</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Fernand Widal Hospital, APHP, INSERM U 705 CNRS UMR 7157</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>INSERM U-825/CIC, Höpital Purpan</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term><term>Depression</term><term>French</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Etat dépressif</term><term>Maladie de Parkinson</term><term>Angoisse anxiété</term><term>Pathologie du système nerveux</term><term>Français</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anxiety has been less extensively studied than depression in Parkinson's disease (PD). The DoPaMiP survey allowed assessing simultaneously anxiety and depressive symptoms in PD and comparing correlations of both symptoms with clinical and therapeutic features of the disease. Cross sectional survey conducted prospectively in 450 ambulatory nondemented PD patients and 98 patients with other disorders than PD. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), parkinsonism using the Unified Parkinson's Disease Rating Scale (UPDRS). Other clinical factors were measured using a structured standardized examination/questionnaire. The mean HADS-A (anxiety) subscore was higher in PD patients than in the others (8.2 ± 3.9 vs. 6.5 ± 3.2, P < 10<sup>-4</sup>) as was the HADS-D (depressive) subscore (6.6 ± 3.8 vs. 3.9 ± 3.2, P < 10<sup>-4</sup>). Patients with possible/probable anxious signs (HADS-A ≥ 8) were more prevalent in PD (51% vs. 29%, P < 10<sup>-4</sup>) as were those with depressive symptoms (40% vs. 10%, P < 10<sup>-4</sup>). Conversely, anxiolytic and antidepressant medications consumption was not different between the 2 groups. Patients with anxious symptoms were more frequently female and younger than those without such symptoms, while those with depressive symptoms had more severe indices of parkinsonism, more comorbidities and lower cognitive function (Mini Mental State Exam). The logistic regression model revealed that patients with depressive symptoms received more frequently levodopa and less frequently a dopamine agonist. Anxiety and depressive symptoms were more frequent in PD patients than in medical control group. Both symptoms were commonly associated in the same PD patients, but were correlated with different clinical/therapeutic features, suggesting different underlying pathophysiological mechanisms.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Bordeaux</li><li>Paris</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name></noRegion><name sortKey="Fourrier, Annie" sort="Fourrier, Annie" uniqKey="Fourrier A" first="Annie" last="Fourrier">Annie Fourrier</name><name sortKey="Grandjean, Helene" sort="Grandjean, Helene" uniqKey="Grandjean H" first="Hélène" last="Grandjean">Hélène Grandjean</name><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><name sortKey="Lepine, Jean Pierre" sort="Lepine, Jean Pierre" uniqKey="Lepine J" first="Jean Pierre" last="Lepine">Jean Pierre Lepine</name><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0303302
|texte= Anxious and Depressive Symptoms in Parkinson's Disease: The French Cross-Sectionnal DoPAMiP Study
}}
| This area was generated with Dilib version V0.6.23. |  |